Atrial fibrillation ablation in heart failure patients: Where do we stand in 2023? – State of the art review

Thomas F. Deering; Sandeep K. Goyal; Ashish A. Bhimani; Michael Hoosien; Ahmadreza Karimianpour; Kavita P. Krishnasamy; Kent R. Nilsson; Abdullah Omar; Dhanunjaya Lakkireddy; Rakesh Gopinathannair; Aashish Katapadi; Christian Sohns

doi:10.1111/pace.14888

Atrial fibrillation ablation in heart failure patients: Where do we stand in 2023? – State of the art review

Thomas F. Deering, Sandeep K. Goyal, Ashish A. Bhimani, Michael Hoosien, Ahmadreza Karimianpour, Kavita P. Krishnasamy, Kent R. Nilsson, Abdullah Omar, Dhanunjaya Lakkireddy, Rakesh Gopinathannair, Aashish Katapadi, Christian Sohns

General Internal Medicine

Research output: Contribution to journal › Review article › peer-review

Abstract

Atrial fibrillation (AF) and heart failure are common overlapping cardiovascular disorders. Despite important therapeutic advances over the past several decades, controversy persists about whether a rate control or rhythm control approach constitutes the best option in this population. There is also considerable debate about whether antiarrhythmic drug therapy or ablation is the best approach when rhythm control is pursued. A brief historical examination of the literature addressing this issue will be performed. An analysis of several important clinical outcomes observed in the prospective, randomized studies, which have compared AF ablation to non-ablation treatment options, will be discussed. This review will conclude with recommendations to guide clinicians on the status of AF ablation as a treatment option when considering management options in heart failure patients with atrial fibrillation.

Original language	English (US)
Pages (from-to)	88-100
Number of pages	13
Journal	PACE - Pacing and Clinical Electrophysiology
Volume	47
Issue number	1
DOIs	https://doi.org/10.1111/pace.14888
State	Published - Jan 2024

Keywords

atrial fibrillation
atrial fibrillation ablation
catheter ablation
heart failure

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1111/pace.14888

Cite this

Deering, T. F., Goyal, S. K., Bhimani, A. A., Hoosien, M., Karimianpour, A., Krishnasamy, K. P., Nilsson, K. R., Omar, A., Lakkireddy, D., Gopinathannair, R., Katapadi, A., & Sohns, C. (2024). Atrial fibrillation ablation in heart failure patients: Where do we stand in 2023? – State of the art review. PACE - Pacing and Clinical Electrophysiology, 47(1), 88-100. https://doi.org/10.1111/pace.14888

Deering, TF, Goyal, SK, Bhimani, AA, Hoosien, M, Karimianpour, A, Krishnasamy, KP, Nilsson, KR, Omar, A, Lakkireddy, D, Gopinathannair, R, Katapadi, A & Sohns, C 2024, 'Atrial fibrillation ablation in heart failure patients: Where do we stand in 2023? – State of the art review', PACE - Pacing and Clinical Electrophysiology, vol. 47, no. 1, pp. 88-100. https://doi.org/10.1111/pace.14888

@article{da9f0b6c86584cf1b1fd32c8c564a16e,

title = "Atrial fibrillation ablation in heart failure patients: Where do we stand in 2023? – State of the art review",

abstract = "Atrial fibrillation (AF) and heart failure are common overlapping cardiovascular disorders. Despite important therapeutic advances over the past several decades, controversy persists about whether a rate control or rhythm control approach constitutes the best option in this population. There is also considerable debate about whether antiarrhythmic drug therapy or ablation is the best approach when rhythm control is pursued. A brief historical examination of the literature addressing this issue will be performed. An analysis of several important clinical outcomes observed in the prospective, randomized studies, which have compared AF ablation to non-ablation treatment options, will be discussed. This review will conclude with recommendations to guide clinicians on the status of AF ablation as a treatment option when considering management options in heart failure patients with atrial fibrillation.",

keywords = "atrial fibrillation, atrial fibrillation ablation, catheter ablation, heart failure",

author = "Deering, {Thomas F.} and Goyal, {Sandeep K.} and Bhimani, {Ashish A.} and Michael Hoosien and Ahmadreza Karimianpour and Krishnasamy, {Kavita P.} and Nilsson, {Kent R.} and Abdullah Omar and Dhanunjaya Lakkireddy and Rakesh Gopinathannair and Aashish Katapadi and Christian Sohns",

note = "Publisher Copyright: {\textcopyright} 2023 Wiley Periodicals LLC.",

year = "2024",

month = jan,

doi = "10.1111/pace.14888",

language = "English (US)",

volume = "47",

pages = "88--100",

journal = "PACE - Pacing and Clinical Electrophysiology",

issn = "0147-8389",

publisher = "Wiley-Blackwell",

number = "1",

}

TY - JOUR

T1 - Atrial fibrillation ablation in heart failure patients

T2 - Where do we stand in 2023? – State of the art review

AU - Deering, Thomas F.

AU - Goyal, Sandeep K.

AU - Bhimani, Ashish A.

AU - Hoosien, Michael

AU - Karimianpour, Ahmadreza

AU - Krishnasamy, Kavita P.

AU - Nilsson, Kent R.

AU - Omar, Abdullah

AU - Lakkireddy, Dhanunjaya

AU - Gopinathannair, Rakesh

AU - Katapadi, Aashish

AU - Sohns, Christian

PY - 2024/1

Y1 - 2024/1

N2 - Atrial fibrillation (AF) and heart failure are common overlapping cardiovascular disorders. Despite important therapeutic advances over the past several decades, controversy persists about whether a rate control or rhythm control approach constitutes the best option in this population. There is also considerable debate about whether antiarrhythmic drug therapy or ablation is the best approach when rhythm control is pursued. A brief historical examination of the literature addressing this issue will be performed. An analysis of several important clinical outcomes observed in the prospective, randomized studies, which have compared AF ablation to non-ablation treatment options, will be discussed. This review will conclude with recommendations to guide clinicians on the status of AF ablation as a treatment option when considering management options in heart failure patients with atrial fibrillation.

AB - Atrial fibrillation (AF) and heart failure are common overlapping cardiovascular disorders. Despite important therapeutic advances over the past several decades, controversy persists about whether a rate control or rhythm control approach constitutes the best option in this population. There is also considerable debate about whether antiarrhythmic drug therapy or ablation is the best approach when rhythm control is pursued. A brief historical examination of the literature addressing this issue will be performed. An analysis of several important clinical outcomes observed in the prospective, randomized studies, which have compared AF ablation to non-ablation treatment options, will be discussed. This review will conclude with recommendations to guide clinicians on the status of AF ablation as a treatment option when considering management options in heart failure patients with atrial fibrillation.

KW - atrial fibrillation

KW - atrial fibrillation ablation

KW - catheter ablation

KW - heart failure

UR - http://www.scopus.com/inward/record.url?scp=85178884251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85178884251&partnerID=8YFLogxK

U2 - 10.1111/pace.14888

DO - 10.1111/pace.14888

M3 - Review article

C2 - 38071456

AN - SCOPUS:85178884251

SN - 0147-8389

VL - 47

SP - 88

EP - 100

JO - PACE - Pacing and Clinical Electrophysiology

JF - PACE - Pacing and Clinical Electrophysiology

IS - 1

ER -

Atrial fibrillation ablation in heart failure patients: Where do we stand in 2023? – State of the art review

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this